Literature DB >> 34394293

Indian scenario of IgA nephropathy: a systematic review and meta-analysis.

Anju Khairwa1.   

Abstract

BACKGROUND: IgA nephropathy (IgAN) is most common primary glomerulopathy. There are variations in prevalence of IgAN and its clinical features in different studies from India. AIM: To summarize overall scenario of IgAN in India.
METHODS: In this systematic review, studies related to IgAN and related renal disease were included. Data searched were PubMed, EMBASE, Google scholar, and Cochrane Database from inception to 31st January 2019.
RESULTS: Total 49 studies (N=2480) were included: 21 studies (N=2309) of primary IgAN; 19 studies (N=21) of Secondary IgAN; four studies (N=133) of IgA vasculitis nephropathy (IgAVN); and five studies (N=17) of IgA dominant nephropathy (IgADN). Prevalence of IgAN was 16.5% in India. Age of affected persons was ranging from 27.2±16.7 to 48.6±21.3 years . Male female ratio was 1.8:1. Clinical features of Primary IgAN, IgAVN, IgADN & Secondary IgAN were microscopic hematuria (49.6%, 44.4%, 15.6% & 59.5%), macroscopic hematuria (5.1%, 0.4%,40.9%,& 35.7%), Subnephrotic proteinuria (42.1%, 29.4%, 23.2%, & 52.3%), nephrotic proteinuria (16.0%, 4.4%, 76.8%,& 47.6%), and hypertension (25.8%,18.3%, 35.5%,& 47.6%).. The 24 hours proteinuria was ranging from 2.6±1.5 to 4.7±2.3 gm/day and serum creatinine (mg/dl) was ranging from 0.9±0 to 3.5±3.9 mg/dl. Histolomorphologically, all type of IgAN showed mesangial hypercellularity and Immunofluorescence revealed IgA deposition..
CONCLUSION: The overall prevalence of primary IgAN in India was 16.5%. The subnephrotic proteinuria and microscopic hematuria were common clinical features.
© 2021 Khairwa A.

Entities:  

Keywords:  IgA Nephropathy; India; histomorphology; prevalence

Mesh:

Substances:

Year:  2021        PMID: 34394293      PMCID: PMC8356571          DOI: 10.4314/ahs.v21i1.21

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


Introduction

IgA nephropathy (IgAN) was first demonstrated by Berger in 1768.1 It is characterized by persistent microscopic hematuria, sub-nephrotic proteinuria, episodic gross hematuria, normal to severe impairment of renal function and hypertension.1,2 Histomorphology varies from normal to chronic glomerulonephritis on renal biopsy of these patients. The most common histomorphology is focal glomerulonephritis. 1,2 On immunofluorescence microscopy (IF), all cases had mesangial deposition of IgA dominantly and less commonly weak staining for IgG and C3. Theelectron microscopy (EM) had presence of mesangial immune complex deposits.1,2 IgA nephropathy is most common primary glomerulonephritis world-wide.3,4 IgA nephropathy mostly diagnosed in certain Asian countries, e.g. Japan, Mainland China, and Singapore.5,6 The incidence of IgA nephropathy ranges from 4.0% to 35.5% in the world.7 IgA nephropathy occurs in all age groups from children to elderly peoples, but it mostly affected age group is 10 to 40 years..8 Clinically features of patients with IgA nephropathy include microscopic hematuria or gross hematuria after one to two days or at a time of fever or upper respiratory tract infection (sore throat), but occasionally it may be associated with gastroenteritis, pneumonia, or urinary tract infection.9 It may remain asymptomatic and diagnosed incidentally or during routine screening of urine.9 The incidence and prevalence of IgA nephropathy is varied in different studies from India.7 Aim of index study was to evaluate the scenario of IgA nephropathy in India.

Methods

We performed a systematic review and meta-analysis to assess the overall scenario of IgAN in India. We included studies of IgA nephropathy and IgA related renal diseases reported from India. Type of studies included were observational studies. We excluded randomized controlled trials and studies from outside of India. Studies including both children and adults were eligible for inclusion in the review. Renal biopsy was considered as reference standard. We searched PubMed (inception to 31st January 2019), EMBASE (inception to 31st January 2019), Google scholar (inception to 31st January 2019) and Cochrane Database Reviews on 31st January 2019. Search strategy for PubMed included (IgA nephropathy) OR IgAN)). We searched EMBASE with key words /exp IgA GN OR IgA nephropathy AND (IgAN), Google scholar with IgA GN or IgA nephropathy and Cochrane Database Reviews with IgA nephropathy. References of included studies were hand searched for additional studies. We assessed the studies for inclusion and extracted data for review. Primary outcome of review was prevalence of IgA nephropathy in India. Secondary outcomes included clinical features, laboratory findings, histopathological pattern, immunofluorescences findings and electron microscopic findings of IgAN from India in comparison to foreign studies.

Statistical methods

The data were entered in excel sheet and analyzed using STATA 12.0 and Cochrane Rev Man 5.1. Continuous outcome data were reported as mean and dichotomous data as percentages. The Newcastle-Ottawa Scale (NOS) was used for assessing quality of nonrandomized studies (cohort and case-control studies).10

Results

The study selection flow diagram is shown in Figure 1. By electronic database search we found a total of 9103 records and screened titles and/or abstracts of all records. After excluding duplicates and irrelevant studies, 62 eligible studies were assessed for full texts. Full texts were found for 49 studies and these were including for qualitative synthesis and meta-analysis.
Figure 1

Study selection flow diagram

Study selection flow diagram Out of 49 studies, 21 studies (2309 cases) were related to Primary IgAN, 19 studies (21 cases) were related to secondary IgA nephropathy (Secondary IgAN), four studies (133 cases) were related to Henoch-Schönlein purpura (HSP) with IgA nephropathy or IgA vasculitis nephritis (IgAVN), and five studies (17 cases) were related to IgA dominant nephropathy (IgADN) (figure 2). The frequency/ prevalence of IgA nephropathy was reported in 14 studies and is shown in Table 1.
Figure 2

Subgrouping of the 49 studies in four

Table 1

Frequencies/prevalence (%) of IgA nephropathy in India

S. No.ReferenceYearStudy population Children, AdultPrevalence of IgA N (%)
1.Chacko et al2011C, A8.6
2Ganesh et al2018C, A21.6
3Siddappa S2011A7.8
4Das et al2015A, C7.5
5Agrawal et al2017A2.6
6Mittal et al2012A8.1
7Chandrika et al2009A, C14.2
8Ramakrishan2016A11.5
9Chacko et al,2007A,C32
10Vanikar et al,2005A16.5
11.Bhuyan et al1992, 87A,C7.24
12.Tiwari et al2016A,C14.3
13Chowdary et al2018A42.0
14Dhanapriya et al2018A5
After pooling the data total prevalence/frequencies 16.5%
C-children, A-Adult,
Subgrouping of the 49 studies in four Frequencies/prevalence (%) of IgA nephropathy in India Clinical and laboratory features of Primary IgA nephropathy, IgA vasculitis nephritis (HSP), IgA dominant nephritis and Secondary IgAN are shown in Table 2. Histomorphology (MEST-C& Haas's classification), Immunofluorescences, and Electron microscopic findings of Primary IgAN, IgAVN (HSP), IgADN and Secondary IgAN are described in Table 3.
Table 2

Clinical and Laboratory features of Primary IgA nephropathy, IgA vasculitis nephritis (HSP), IgA dominant nephritis and Secondary IgAN

S.No.Main clinical featuresPrimary IgA nephropathyIgA vasculitis nephritis(HSP)IgA dominant nephritisSecondary IgAN
1.Mean age (years)31.7±13.837.5±15.848.6±21.327.2±16.7
2.Male : female1.93:11.07:11.64:12:1
3.Asymptomatic urinary abnormalities (%)5.51.409.5
4.Macroscopic hematuria(%)5.10.4440.9435.71
5.Microscopic hematuria(%)49.644.4915.6459.57
6.Subnephrotic proteinuria (>1g/d) (%)42.129.4223.2952.38
7Nephrotic range proteinuria (>3g/d) (%)16.044.4476.8847.61
8.Loin or abdominal pain(%)1.861.7204.7
9.Hypertension(%)25.818.3935.547.61
10.Infection-related exacerbations(%)10.319.1447.054.7
11.Skin Rashes(%)099.2400
12.GIT manifestation(%)054.835.80
13.Arthritis/arthralgia(%)078.5800
14.Duration of symptoms5.40±3.23.91±0.592.87±1.842.81±3.9
15.Raised serum creatinine3.04±2.60.9±03.21±203.5±3.9
16.Reduced e-GFR59.54±19.3-63.6±078±0
17.24 h urine protein (g/d)2.6±1.53.2±03.5±0.24.7±2.3
18.Serum C3 level reduced (%)00.0688.470
Table 3

Histomorphology (MEST & Haas's classification, Immunofluorescences and Electron microscopic findings in primary IgA nephropathy, IgA vasculitis nephritis (HSP), IgA dominant nephritis and Secondary IgAN

S.No.Types IgANInvestigations
Histomorphology(%)Immunofluorescence (%)Electron microscopy(%)
MEST-C classificationHaas's classificationSkin biopsyIgGIgAIgMC3F.H.MeDSubEnDSubEpDBoth
Renal biopsy
1.Primay IgANMe-59 En-10.4 SG-20.9 C1–3.6 C2–5.3 T0-2.8 T1-11.5 T2-9.6 N-1.03Cl I -11.1 Cl II-10.6 Cl III-13 Cl IV-7.5 Cl V-16.2-1.6 100 4.54.60.2 26.4 0.580 17.3
2.IgAVNMe-9.7 En-6.7 SG-0.7 C1-2.2 T0-2.2-LC-33.80 100 0 22.5 0----
3.IgADNMe-29.4 En-47.0 C2-58.8--12.21001 89.7 005.8 11.7 5.8
4.Secondary IgANMe-95.2 En-23.8 SG-33.3 C1-19 T0-14.2--16.6 100 5.9 9.5 09.504.70

Me-Mesangial proliferation, En-Endocapillary proliferation, SG-Segmental Glomerulosclerosis, C1- <25% Cellular/fibrocellular crescent, C2- >25%Cellular/Fibrocellular crescent, T0- ≤25%TA/IF T1- 26% to 50% TA/IF, T2->50%TA/IF, N-Normal, Cl- Class, MeD-mesangial deposition, SubEnD-subenothelial deposition, SubepD-subepithelial deposition, Both-MeD+EnD, ,HistoM-histomorphology, LC- leukocytoclastic vasculitis ,F.H.-Full House

Clinical and Laboratory features of Primary IgA nephropathy, IgA vasculitis nephritis (HSP), IgA dominant nephritis and Secondary IgAN Histomorphology (MEST & Haas's classification, Immunofluorescences and Electron microscopic findings in primary IgA nephropathy, IgA vasculitis nephritis (HSP), IgA dominant nephritis and Secondary IgAN Me-Mesangial proliferation, En-Endocapillary proliferation, SG-Segmental Glomerulosclerosis, C1- <25% Cellular/fibrocellular crescent, C2- >25%Cellular/Fibrocellular crescent, T0- ≤25%TA/IF T1- 26% to 50% TA/IF, T2->50%TA/IF, N-Normal, Cl- Class, MeD-mesangial deposition, SubEnD-subenothelial deposition, SubepD-subepithelial deposition, Both-MeD+EnD, ,HistoM-histomorphology, LC- leukocytoclastic vasculitis ,F.H.-Full House

Discussion

We found combined prevalence of IgAN as 16.5% of in India. The prevalence of IgA nephropathy showed considerable variations (0.8–47%) among geographic regions with different renal biopsy practices.3,6,25–26 The prevalence in India was lower than certain Asian counties e.g. Japan (47.4%) and China(45%).25–26 We found higher prevalence of IgAN in comparison to study by Seedate et al (13.3%) from African country Natal done on Indians.27 The IgA nephropathy was uncommon (0.8%) in African blacks.27 The frequencies of IgAN was higher in India than the studies from United States that had prevalence of 10.8% and 9.4%.28 We were unable to pool the data for incidence because the studies were not accurately defined the incidence. Primary IgAN and Secondary IgAN was found in younger age groups and it is similarly reported by other studies29,30 Males were more commonly effected than females and our findings corroborated with other studies27,29 We found that IgADN was presented in higher age group (48.6±21.3) than Primary IgAN, IgAVN, and Secondary IgAN. Similarly, Nasr et al reported IgADN in elderly age group.31 We also found rapid onset of symptoms in primary IgAN and Secondary IgAN as described by other studies.9,32 It was different from PIGN (post infection glomerulonephritis), which had a period of latency (1–2 weeks) after the symptoms of infection.33 Infection related exacerbations were associated maximum with IgADN (47%) followed by IgAVN (19%). The similar observation was reported in a study by Satoskar et al.34 Episodic macroscopic hematria, nephrotic range proteinuria and hypertension had been typically associated with IgADN.35 We found the similar observations. Microscopic hematuria (49.6–59.5%) and subnephrotic proteinuria (42.1–52.3%) were more frequent in primary and secondary IgAN and it correlated with other studies.36–38 We found that rapidly progressive renal failure was associated with IgADN and secondary IgAN than primary IgAN and IgAVN and similar trend had been demonstrated by other studies.35,37 Similar to Nasr et al., we also found hypocomplementemia more in IgADN in comparison to primary and secondary IgAN and IgAVN.39 Histomorphology of primary and secondary IgAN ranged from normal to chronic glomerulonephritis and it was similar to various other studies.29, 36, 40,41 On IF, most biopsies showed predominantly IgA deposition in primary and secondary IgAN at mesangial region and same had been demonstrated by many studies.42–44 Electron microscopy depicted mesangial electron-dense deposition followed by both (mesangial and subendothelial) deposition in primary and secondary IgAN, and similar findings were reported by Haas et al.45 IgAVN (HSP) showed highly variable histomorphology of glomeruli ranging from normal to diffuse proliferative and crescentic glomerulonephritis. 46 Skin biopsy demonstrated leukocytoclastic vasculitis in (33.8%) cases, which was less than other study.47 The limitation of this study was that we were unable to pool incidence of IgAN because none of studies clearly defined the data.

Conclusion

The IgA nephropathy was more prevalent in India with most common subgroup being primary IgAN. Subnephrotic proteinuria and microscopic hematuria were common clinical presentation of IgAN. Secondary IgAN and IgADN had more rapidly-progressive renal failure than primary IgAN and IgAVN.
  41 in total

1.  IgA nephropathy in Kerala, India: a retrospective study.

Authors:  B Kumari Chandrika
Journal:  Indian J Pathol Microbiol       Date:  2009 Jan-Mar       Impact factor: 0.740

2.  A reevaluation of routine electron microscopy in the examination of native renal biopsies.

Authors:  M Haas
Journal:  J Am Soc Nephrol       Date:  1997-01       Impact factor: 10.121

3.  Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases.

Authors:  M Haas
Journal:  Am J Kidney Dis       Date:  1997-06       Impact factor: 8.860

4.  IgA glomerulonephritis in Japan.

Authors:  Y Ueda; O Sakai; M Yamagata; T Kitajima; K Kawamura
Journal:  Contrib Nephrol       Date:  1975       Impact factor: 1.580

Review 5.  IgA nephropathy in India: what we do know.

Authors:  Bobby Chacko
Journal:  Ren Fail       Date:  2011       Impact factor: 2.606

6.  Incidence of pediatric IgA nephropathy.

Authors:  Yasushi Utsunomiya; Takayuki Koda; Tadashi Kado; Sinichi Okada; Atsushi Hayashi; Susumu Kanzaki; Tsunakiyo Kasagi; Hiroshi Hayashibara; Teruo Okasora
Journal:  Pediatr Nephrol       Date:  2003-04-29       Impact factor: 3.714

7.  Outcomes of renal transplantation in patients with immunoglobulin A nephropathy in India.

Authors:  B Chacko; J T George; N Neelakantan; A Korula; J K Chakko
Journal:  J Postgrad Med       Date:  2007 Apr-Jun       Impact factor: 1.476

8.  IgA nephropathy: a syndrome of uniform morphology, diverse clinical features and uncertain prognosis.

Authors:  A R Clarkson; A E Seymour; A J Thompson; W D Haynes; Y L Chan; B Jackson
Journal:  Clin Nephrol       Date:  1977-11       Impact factor: 0.975

9.  IgA associated glomerulonephritis.

Authors:  U N Bhuyan; S C Dash; R N Srivastava; S C Tiwari; K K Malhotra
Journal:  J Assoc Physicians India       Date:  1992-05

10.  IgA-dominant Infection-related Glomerulonephritis in India: A Single-center Experience.

Authors:  J Dhanapriya; T Balasubramaniyan; S P Maharajan; T Dineshkumar; R Sakthirajan; N Gopalakrishnan; M Nagarajan
Journal:  Indian J Nephrol       Date:  2017 Nov-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.